Company intelligence / Profile preview

Curetopia

Ownership: Private
Development stage: Preclinical

Overview

Curetopia has identified two drug repurposing candidates for the rare genetic disorder AARS2 deficiency using a high-throughput yeast-based screening process. The organization is filing a provisional patent and working with affected families to launch parallel N-of-1 studies. No therapies have yet reached late-stage clinical trials or commercialization, but the approach is notable for its speed and capital efficiency compared to traditional biotech models[1][3].

Therapeutic areas: Neurology
Modalities: Drug repurposing (primarily small molecules identified from pre-approved drugs)[1][2][3][4]
Industry: Biotech

Partnerships

COMBINEDBrain (drug screening services partnership)[2]Unravel Biosciences (drug screening services partnership)[2]

Beyond the preview

Go deeper on Curetopia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curetopia.

Explore the full profile